The HICOOL 2025 Global Entrepreneur Summit officially opened on October 16th at the Beijing International Convention and Exhibition Center. As a highly anticipated international innovation and entrepreneurship platform, the HICOOL Competition has consistently dedicated itself to converging global intelligence and promoting the integration of cutting-edge technology and industry. In this year's competition, OptoSeeker Biotech, leveraging its solid technical foundation and clear industrialization pathway, distinguished itself amidst fierce competition and successfully secured the Third Prize in the HICOOL 2025 Global Entrepreneur Competition.

OptoSeeker Biotech and the National Major Science and Technology Infrastructure for Translational Medicine (Sichuan)/State Key Laboratory of Biotherapy at Sichuan University have officially launched a "Single-Cell Optofluidic Intelligent Screening Joint Demonstration Laboratory" in Chengdu.

August 12, 2025 – OptoSeeker Biotech (Shenzhen) Co., Ltd. (hereinafter referred to as OptoSeeker Biotech) and MGI have announced a strategic partnership. This collaboration will leverage both parties' technological and platform strengths in the life sciences to jointly create an antibody discovery platform covering the entire workflow of "screening-sequencing-data analysis," accelerating the industrialization of life science instruments.

Recently, Optoseeker Biotech welcomed a visit from Professor Huabing Yin of the School of Engineering at the University of Glasgow. Professor Yin's visit brought a leading-edge international scientific perspective and opportunities for collaboration to Optoseeker Biotech, as both parties engaged in in-depth discussions on digital microfluidics and single-cell analysis technology.

Optoseeker Biotech, an innovator in advanced life science instrumentation, and BioMap, a pioneer in life science AI, today announced a strategic collaboration set to dramatically accelerate the development of novel antibody therapeutics

OptoSeeker Secures Tens of Millions in Angel+ Round Funding